Abstract:Background:Patients harboring anaplastic lymphoma kinase (ALK) or rearranged during transfection (RET) rearrangements are usually diagnosed at a relatively late stage with nodal and distant metastasis, and rapid progression course of ALK/RET fusion-positive lung cancer were well-known. However, clinical characteristics and course of pre-/minimally invasive lung adenocarcinoma harboring ALK or RET fusions are poorly described. Identifying patients with gene fusions at early stage may offer surgical options that could cure those patients.Methods:We retrospectively included patients with surgically resected pre-/minimally invasive lung adenocarcinomas harboring epidermal growth factor receptor (EGFR) mutations or ALK/RET rearrangements, and further compared the patient clinical characteristics, nodule natural course, and survival outcomes. Radiological characteristics including ground-glass component, cystic airspace, pleural attachment, etc. were specially assessed for this study. EGFR (exons 18-22) was detected by Sanger sequencing and quantitative real-time polymerase chain reaction (qRT-PCR) was used to analyze the ALK/RET rearrangements. Lung cancer-specific survival (LCSS), relapse-free survival (RFS), and overall survival (OS) were all evaluated.Results:Of 238 patients with pre-/minimally invasive lung adenocarcinomas, 226 patients had EGFR mutations, 7 patients had ALK fusions, and 5 patients had RET fusions. Average age at surgery was 45.3 years for ALK/RET-positive group and 52.6 years for EGFR-positive group (P=0.049). Radiologically, among the 12 patients with ALK/RET fusions, the majority of lesions (10/12) manifested as mixed ground-glass opacities (mGGOs), which was significantly more prevalent when compared with patients with EGFR mutations (83.4% vs. 24.3%, P<0.001). Moreover, a substantial proportion of cystic airspace was found in ALK/RET-positive group but not in EGFR-positive group (66.7% vs. 14.2%, P<0.001). Among four patients with ALK/RET fusions undergoing surveillance over 1 year before surgery, two of them developed rapid radiologic progression. The 5-year LCSS and RFS were 100%, 100% for ALK/RET-positive group, and 100%, 100% for EGFR-positive group, respectively.Conclusions:ALK/RET-positive pre-/minimally invasive lung adenocarcinomas were mostly characterized as mGGOs with cystic airspace developing rapid nodule progression, and no recurrence occurred during long-term follow-up after resection. This provides insights into proper curative surgery timing in the management of patients with gene fusions. However, these findings must be treated with caution and validated in future multi-center studies with larger sample size.

Clinicopathologic Characteristics of ALK Rearrangements in Primary Lung Adenocarcinoma with Identified EGFR and KRAS Status.

Clinical Characteristics and Outcomes of Patients with Primary Lung Adenocarcinoma Harboring Alk Rearrangements Detected by Fish, Ihc, and Rt-Pcr

Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement

Concomitant Mutation Status of ALK-rearranged Non-Small Cell Lung Cancers and Its Prognostic Impact on Patients Treated with Crizotinib

Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations

ALK and ROS1 Rearrangements, Coexistence and Treatment in Epidermal Growth Factor Receptor-Wild Type Lung Adenocarcinoma: a Multicenter Study of 732 Cases

Association of EGFR Mutation or ALK Rearrangement with Expression of DNA Repair and Synthesis Genes in Never‐smoker Women with Pulmonary Adenocarcinoma

Gene Status and Clinicopathologic Characteristics of Lung Adeno-Carcinomas with Mediastinal Lymph Node Metastasis

Echinoderm Microtubule-Associated Protein-Like 4-Anaplastic Lymphoma Kinase Rearrangement and Epidermal Growth Factor Receptor Mutation Coexisting in Chinese Patients with Lung Adenocarcinoma.

Clinicopathological Characteristics and Outcomes of ROS1-rearranged Patients with Lung Adenocarcinoma Without EGFR, KRAS Mutations and ALK Rearrangements.

Dissecting the Clinicopathological, Genomic, and Prognostic Significance of ALK Rearrangement in Resected Lung Adenocarcinoma

Clinical Characteristics and Progression of Pre-/Minimally Invasive Lung Adenocarcinoma Harboring ALK or RET Rearrangements: a Retrospective Cohort Study.

Prevalence and clinicopathological characteristics of ALK fusion subtypes in lung adenocarcinomas from Chinese populations

Intratumoral Heterogeneity Of Alk-Rearranged And Alk/Egfr Co-Altered Lung Adenocarcinoma

Comparison of clinical and radiological characteristics between anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation in treatment naïve advanced lung adenocarcinoma.

Immunohistochemical screening and fluorescence in situ hybridization confirmation of ALK translocation in lung adenocarcinoma and its clinicopathological significance: a single-center large-scale investigation of Chinese patients.

Clinicopathological Features of ALK Expression in 9889 Cases of Non-small-Cell Lung Cancer and Genomic Rearrangements Identified by Capture-Based Next-Generation Sequencing: A Chinese Retrospective Analysis.

Different Histopathology but the Same Clonality: ALK Rearrangement in a Patient with Metastatic Non-Small-cell Lung Cancer.

Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers

Prognostic Significance of Anaplastic Lymphoma Kinase Rearrangement in Patients with Completely Resected Lung Adenocarcinoma

Retrospective Study of Clinicopathologic Factors Associated with Alk Rearrangement and Survival Outcome in Chinese Patients (PTS) with NSCLC